LDS/Medical Tests/Guardant360 TissueNext™, Lung and Breast Cancer Therapy Management

Guardant360 TissueNext™, Lung and Breast Cancer Therapy Management

Non-small cell lung cancer (NSCLC) accounts for approximately 85% of all lung cancer cases. Effective treatment relies on identifying both histological and genomic characteristics of individual patients, enabling personalized therapeutic approaches and optimizing treatment responses. Traditional tissue biopsies, while widely used, have limitations, including their invasive nature, sample inadequacy, and potential for tumor heterogeneity.

Guardant360 TissueNext™ is a non-invasive liquid biopsy assay designed to detect somatic mutations in 74 genes associated with NSCLC and breast cancer. The test analyzes circulating tumor DNA (ctDNA) in blood samples, allowing for the identification of key genetic variations such as single nucleotide polymorphisms (SNPs), insertions, deletions, fusions, and rearrangements for 55 specific genes relevant to NSCLC. This facilitates informed clinical decision-making, particularly in patients who are unable to undergo tissue biopsy or have inconclusive tissue-based genetic profiling.

  • Identifies patients with NSCLC or breast cancer who may benefit from targeted therapy
  • Assists in selecting mutation-specific therapies, guiding precision oncology approaches
  • Monitors tumor evolution and acquired resistance in response to therapy

The presence of specific mutations in the tested gene panel indicates potential benefit from targeted therapies. Notable indications include:

Cancer Type Marker Indicated Therapy

  • NSCLC EGFR exon 19 deletions, L858R, T790M TAGRISSO® (osimertinib)
  • NSCLC EGFR exon 20 insertions RYBREVANT® (amivantamab-vmjw)
  • NSCLC ERBB2/HER2 activating mutations (SNVs and exon 20 insertions) ENHERTU® (fam-trastuzumab deruxtecan-nxki)
  • NSCLC KRAS G12C LUMAKRAS™ (sotorasib)

Breast Cancer ESR1 missense mutations (codons 310-547) ORSERDU™ (elacestrant)

A negative result indicates no detectable actionable mutations and no predicted benefit from the targeted therapies listed above. However, it does not rule out the presence of mutations below the assay's detection threshold.

Negative for mutations analyzed

Next-generation sequencing (NGS)/Massively Parallel Sequencing (MPS).

Whole blood (two EDTA tubes required).

Stability

  • Ambient: 3 days
  • Refrigerated: 7 days
  • Frozen: Unstable
EGFR mutation analysis (for comprehensive assessment of EGFR alterations), CEA (Carcinoembryonic Antigen) testing (for prognostic evaluation), Sputum cytology (if blood-based molecular testing is inconclusive).
1-3 weeks.
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login